Loading…
Loading…
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of 30 U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Is PJP's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.
DUBAI, United Arab Emirates--(BUSINESS WIRE)--Papa Johns (PJP Investments Group), has partnered with Blink to bring a mobile-first digital experience to its 1,300-strong workforce.
Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.
The Invesco S&P 500 Equal Weight Health Care ETF offers a lower expense ratio and broader diversification than the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has generated higher 1-year and 5-year total returns while maintaining lower price volatility.
The VanEck Pharmaceutical ETF offers a lower expense ratio of 0.36% compared to 0.58% for the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has delivered a higher 1-year total return of 41% relative to 31% for the VanEck fund.